Acute Administration of Angiotensin Converting Enzyme Inhibitors in Thrombolysed Myocardial Infarction Patients Is Associated with a Decreased Incidence of Heart Failure, but an Increased Re-Infarction Risk

Author： Voors Adriaan   Kam Pieter   Berg Maarten   Borghi Claudio   Hochman Judith   Veldhuisen Dirk   Gilst Wiek  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.19, Iss.2, 2005-03, pp. : 119-124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Treatment with Angiotensin-Converting Enzyme Inhibitors, Beta-Blockers or a Combination of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Low-Risk Patients after Acute Myocardial Infarction: The ABC Study

By  

Heart Drug, Vol. 1, Iss. 1, 2001-03 ,pp. : 20-25

Karger

Access to resources Recommend Favorite

Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction

By Salam Amar M  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 3, 2003-03 ,pp. : 501-507

Informa Healthcare

Access to resources Recommend Favorite

The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction

By Kvan Elena   Reikvam Aasmund  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 3, 2004-05 ,pp. : 205-210

Springer Publishing Company

Access to resources Recommend Favorite

Angiotensin Converting Enzyme Inhibitors: Should They be Used Early Post Myocardial Infarction?

By Pitt Bertram  

Cardiovascular Drugs and Therapy, Vol. 19, Iss. 2, 2005-03 ,pp. : 103-104

Springer Publishing Company

Access to resources Recommend Favorite

Cost of Heart Failure in Patients Receiving -Blockers and Angiotensin-Converting Enzyme Inhibitors

By Weintraub W.S.  

Clinical Drug Investigation, Vol. 24, Iss. 5, 2004-01 ,pp. : 255-264

Adis International

Access to resources Recommend Favorite